Biotech investors always seem to be looking for the next big thing. These days, many are going under the hood of the CAR-T.
CAR-T is short for chimeric antigen receptor T-cell therapy, a version of immunotherapy, which deploys the patient’s own immune system to fight cancer. First developed in academic labs, CAR-T therapies have been picked up by big pharma Novartis (NYSE:NVS) as well as a number of small startups.
Help employers find you! Check out all the jobs and post your resume.
